Tiziana Life Sciences PLC Tiziana at BIO CEO & Investor Digital Conference
February 16 2021 - 9:37AM
RNS Non-Regulatory
TIDMTILS
Tiziana Life Sciences PLC
16 February 2021
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Tiziana Life Sciences to Present at the BIO CEO & Investor
Digital Conference
NEW YORK and LONDON - 16 February 2021 (GLOBE NEWSWIRE) -
Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or
the "Company"), a biotechnology company focused on innovative
therapeutics for oncology, inflammation, and infectious diseases,
today announced that it is presenting at the BIO CEO & Investor
Digital Conference, 16-18(th) February 2021.
Dr. Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences,
commented, "I look forward to sharing our exciting story with
conference attendees. With the release of our topline data from our
COVID-19 trial, multiple Phase 2 trial launches expected in 2021,
and the potential application of Foralumab in a wide range of
autoimmune and inflammatory diseases in the longer-term, we are
well positioned to achieve a series of important milestones in the
months and quarters ahead."
Tiziana Life Sciences presentation will be accessible on demand
during the virtual event for all registered attendees.
Please visit http://www.tizianalifesciences.com/about-us/ or
www.TLSAinfo.com for more information and to view the latest
investor presentation.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules to
treat human disease in oncology and immunology. In addition to
Milciclib, the Company is also developing Foralumab for liver
diseases. Foralumab is the only fully human anti-CD3 monoclonal
antibody in clinical development in the world. This Phase 2
compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as nonalcoholic steatohepatitis
(NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes
(T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
U.S. Investor Contact:
RedChip Companies, Inc.
Dave Gentry
407-491-4498
dave@redchip.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPUCWPUPGGCQ
(END) Dow Jones Newswires
February 16, 2021 09:37 ET (14:37 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Oct 2023 to Oct 2024